Artal Group S.A. Silence Therapeutics PLC Transaction History
Artal Group S.A.
- $1.86 Billion
- Q1 2024
A detailed history of Artal Group S.A. transactions in Silence Therapeutics PLC stock. As of the latest transaction made, Artal Group S.A. holds 2,779,619 shares of SLN stock, worth $55.5 Million. This represents 3.24% of its overall portfolio holdings.
Number of Shares
2,779,619
Previous 2,779,619
-0.0%
Holding current value
$55.5 Million
Previous $60 Million
-0.0%
% of portfolio
3.24%
Previous 3.24%
Shares
5 transactions
Others Institutions Holding SLN
# of Institutions
63Shares Held
27.1MCall Options Held
0Put Options Held
0-
Tcg Crossover Management, LLC Palo Alto, CA3.3MShares$65.7 Million7.49% of portfolio
-
Lombard Odier Asset Management (Usa) Corp New York, NY2.39MShares$47.7 Million1.25% of portfolio
-
Lombard Odier Asset Management (Europe) LTD London, X02.24MShares$44.6 Million4.48% of portfolio
-
Redmile Group, LLC San Francisco, CA2.03MShares$40.5 Million1.73% of portfolio
-
Deep Track Capital, LP Greenwich, CT1.64MShares$32.8 Million1.17% of portfolio
About Silence Therapeutics plc
- Ticker SLN
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,888,400
- Market Cap $716M
- Description
- Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated...